Lateral Pharma (Lateral) is a privately-owned and funded biotechnology company that has discovered a new host-protective biological pathway. It is focussed on developing its portfolio of drugs for the treatment of neuropathic pain and infectious & inflammatory respiratory diseases.
In that endeavor Lateral has discovered a new class of naturally-derived peptide motifs and their novel target family of receptor proteins that act to restore normal tissue function in mammals under conditions of damage, attack and cellular stress. These small synthetic peptides, derived from growth hormone and at least four other mammalian proteins, have proven active in animal models of neuropathic pain and respiratory disease (including severe influenza A infection, SARS-CoV-2, RSV and chronic obstructive pulmonary disease (COPD). .
Lateral Pharma is a Melbourne, AU-based biotechnology company that commenced operations in May 2015, with a focus on repurposing LAT8881; a Phase II orally-available compound with extensive human safety data, into new high potential pain and respiratory indications. We leverage off the prior owners >$50m expenditure on formal pre-clinical & clinical development of LAT8881. This enables immediate phase 2 human clinical studies of our lead compound. Lateral is also investigating the further clinical development of a portfolio of newly discovered peptide motifs and their receptor targets that act to restore normal tissue function and health in mammals under conditions of damage, attack and cellular stress.
Lateral’s clinical development program is currently focussed on Phase 1/2 studies with its lead drug, LAT8881, being delivered IV in the treatment of neuropathic pain, aiming to demonstrate clinical proof-of-concept in humans.
Lateral is currently focussing its resources on the treatment of neuropathic pain and in that regard is working within the Preclinical Screening Platform for Pain funded by NIH for two of its lead peptides. In noting the significant efficacy of LAT8881 and related LAT peptides in animal models of respiratory disease, if funding allows, Lateral also aims to initiate clinical trials in respiratory disease patients. The aim would be to restore normal tissue and cellular function and improve the overall health in patients with a range of respiratory diseases including Influenza, RSV, long-COVID or COPD patients where their condition has been exacerbated by lung infections.
Lateral also has an active preclinical screening program focussed on the identification of lower molecular weight drug candidates that can add additional value to the clinical development portfolio.